Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.
This study is a Phase 3, multicenter, randomized, double-blind, placebo- and active-controlled parallel-group study to evaluate the efficacy and safety of cebranopadol in the treatment of postoperative pain following primary unilateral bunionectomy with first metatarsal osteotomy. The study will be conducted in 3 phases: Screening, Treatment, and Follow-up.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cebranopadol | Experimental | once daily for 3 days |
|
| Oxycodone IR | Active Comparator | four times per day for 3 days |
|
| Placebo | Placebo Comparator | four times per day for 3 days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cebranopadol | Drug | once daily for 3 days |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Pain NRS area under the curve: cebranopadol vs. placebo | 2-48 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of subjects who require opioid rescue medication | 1-7 Days | |
| Global Assessment of Satisfaction | 1-7 Days | |
| Total oxycodone rescue consumption |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Respiratory Safety Events | 1-7 Days |
Key Inclusion Criteria Before Surgery:
Key Exclusion Criteria Before Surgery:
Immediate Postoperative Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Todd M Bertoch, MD | Cenexel JBR | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ALLEVIATE 2 Site 001108 | Sheffield | Alabama | 35660 | United States | ||
| ALLEVIATE 2 Site 001106 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Oxycodone IR | Drug | four times per day for 3 days |
|
|
| Placebo Only | Drug | four times per day for 3 days |
|
| Placebo | Drug | three times per day for 3 days |
|
| 1-7 Days |
| Little Rock |
| Arkansas |
| 72211 |
| United States |
| ALLEVIATE 2 Site 001103 | Tampa | Florida | 33613 | United States |
| ALLEVIATE 2 Site 001102 | Atlanta | Georgia | 30331 | United States |
| ALLEVIATE 2 Site 001107 | Overland Park | Kansas | 66212 | United States |
| ALLEVIATE 2 Site 001105 | Pasadena | Maryland | 21122 | United States |
| Alleviate 2 001113 | Houston | Texas | 77043 | United States |
| ALLEVIATE 2 Site 001104 | McAllen | Texas | 78501 | United States |
| ALLEVIATE 2 Site 001111 | San Antonio | Texas | 78240 | United States |
| ALLEVIATE 2 Site 001101 | Salt Lake City | Utah | 84107 | United States |
| ID | Term |
|---|---|
| D059787 | Acute Pain |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000589289 | 6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine |
| D010098 | Oxycodone |
| ID | Term |
|---|---|
| D003061 | Codeine |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
Not provided
Not provided